Teva Loses Amgen Spying Suit Over Blood Drug Secrets
Law360, Los Angeles (April 30, 2013, 8:26 PM EDT) -- A California federal judge on Monday dismissed a suit alleging Amgen Inc. hired a “competitive intelligence” consulting firm to steal trade secrets about Teva Pharmaceuticals USA Inc.'s generic versions of blood drugs, finding Teva had no factual basis for its misappropriation claim.
U.S. District Judge Cormac J. Carney ruled that Teva's five other claims — including fraud, unfair competition and tortious interference with prospective business advantage — were preempted by the California Uniform Trade Secrets Act and Teva had not alleged sufficient facts to support its CUTSA claim that Amgen, acting with consulting firm Health IQ, stole proprietary information related to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!